{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-031163","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.343162+00:00","generated_at":"2026-05-31T09:58:10.261996+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Oragenics: concussion drug ONP-002 shows no genotoxicity in animal study; Phase II planned","bullets":["ONP-002 completed in vivo micronucleus assay; no evidence of genetic mutations or DNA damage across low, medium, high doses.","Study conducted under GLP conditions with VivoPharm; supports safety for planned Phase II clinical trial for concussion.","Company previously reported safety margin in two-species tox and cardiac safety (GLP hERG); now genotoxicity cleared.","Concussion affects ~69M annually globally; post-concussion symptoms cause long-term disability in up to 20% of patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-031163","json":"https://secwatch.observer/filing/0001493152-24-031163.json","markdown":"https://secwatch.observer/filing/0001493152-24-031163.md","text":"https://secwatch.observer/filing/0001493152-24-031163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224031163/0001493152-24-031163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224031163/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:58:10.261996+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}